All In Biotech

Drug Trial Radar · NCT00001061

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

167

Actual

Start

Not stated

Primary completion

Not stated

Study completion Mar 1998

Sponsor

Sponsor type
NIH
Collaborators
Facet Biotech
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the effect of MSL 109, human monoclonal anti-cytomegalovirus (CMV) antibody, on time to progression of CMV retinitis. To determine the safety and pharmacokinetic profile of MS 109. To evaluate the relationship between pharmacokinetic measurements of MSL 109 and efficacy and virologic markers. Therapeutic agents currently available for CMV retinitis are limited by their inherent toxicities and short half-lives which require frequent intravenous dosing. Alternatively, MSL 109 has demonstrated safety and effectiveness in neutralizing CMV isolates at concentrations easily maintained in AIDS patients.

Conditions

  • Cytomegalovirus Retinitis
  • HIV Infections

Interventions

  • SevirumabDrug

  • Foscarnet sodiumDrug

  • GanciclovirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Therapeutics CRS

    Birmingham, Alabama

  • USC CRS

    Los Angeles, California

  • Santa Clara Valley Med. Ctr.

    San Jose, California

  • Stanford CRS

    Stanford, California

  • University of Colorado Hospital CRS

    Aurora, Colorado

  • Univ. of Miami AIDS CRS

    Miami, Florida

  • Queens Med. Ctr.

    Honolulu, Hawaii

  • Univ. of Hawaii at Manoa, Leahi Hosp.

    Honolulu, Hawaii

  • Cook County Hosp. CORE Ctr.

    Chicago, Illinois

  • Rush Univ. Med. Ctr. ACTG CRS

    Chicago, Illinois

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic

    Indianapolis, Indiana

  • Massachusetts General Hospital ACTG CRS

    Boston, Massachusetts

  • Beth Israel Deaconess - East Campus A0102 CRS

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS

    Boston, Massachusetts

  • Washington U CRS

    St Louis, Missouri

  • SUNY - Buffalo, Erie County Medical Ctr.

    Buffalo, New York

  • Univ. of Rochester ACTG CRS

    Rochester, New York

  • Univ. of Cincinnati CRS

    Cincinnati, Ohio

  • Case CRS

    Cleveland, Ohio

  • Hosp. of the Univ. of Pennsylvania CRS

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.